Ignite Creation Date:
2024-05-06 @ 9:18 AM
Last Modification Date:
2024-10-26 @ 12:13 PM
Study NCT ID:
NCT02955290
Status:
RECRUITING
Last Update Posted:
2023-11-08
First Post:
2016-11-02
Brief Title:
CIMAvax Vaccine Nivolumab and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
Sponsor:
Roswell Park Cancer Institute
Organization:
Roswell Park Cancer Institute
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Advanced Head and Neck Squamous Cell Carcinoma |
| Lung Non-Small Cell Carcinoma |
| Metastatic Lung Non-Small Cell Carcinoma |
| PD-L1 Positive |
| Recurrent Head and Neck Squamous Cell Carcinoma |
| Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 |
| Stage III Lung Cancer AJCC v8 |
| Stage IIIA Lung Cancer AJCC v8 |
| Stage IIIB Lung Cancer AJCC v8 |
| Stage IIIC Lung Cancer AJCC v8 |
| Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 |
| Stage IV Lung Cancer AJCC v8 |
| Stage IVA Lung Cancer AJCC v8 |
| Stage IVB Lung Cancer AJCC v8 |
| Unresectable Lung Non-Small Cell Carcinoma |
| Advanced Squamous Non-Small Cell Lung Carcinoma |
Keywords: